Published on : Aug 23, 2017
Albany, New York, August 23, 2017: Pediatric brain tumors and brain cancer, while rare, are considered to be the deadliest of all childhood cancers. While the incidence rate may be relatively low, with nearly 3,400 new cases diagnosed annually in the United States, the mortality rate of children with these types of cancers is significantly higher than other childhood cancers and diseases. It has been analyzed that research is the key component in the battle to cure childhood brain cancer. Recently, a new study providing comprehensive insights of the ongoing therapeutic pipeline research and development for Medulloblastoma has been added to the vast repository of Market Research Hub (MRH), with the title of “Medulloblastoma-Pipeline Insight, 2017”.
Medulloblastomas are the most common malignant brain tumour of childhood, accounting for 15-20% of all childhood brain tumours. They are also seen in adults but only account for 0.4-1.0% of adult brain tumours. If the tumor is determined to be a medulloblastoma, current treatment consists of surgically removing as much tumor as possible, followed by craniospinal (brain and spine) radiation and/or chemotherapy. For infants and children under the age of three, chemotherapy is used to delay or even remove the need for radiation therapy. While radiation therapy has proven effective for most medulloblastoma, scientists are still looking for new ways to lower the potential side effects of this treatment.
Firstly, the report starts with the overview of medulloblastoma and its therapeutic development. Under the therapeutic development, the pipeline overview, pipeline products for medulloblastoma that are under development and in the clinical stage are detailed along with product description, R&D and product development activities. Further, the study provides the therapeutic assessment of medulloblastoma, which assesses the target, mechanism of action, route of administration and molecule type. Overall, the report provides a complete understanding of the pipeline activities which comprises all clinical, pre-clinical and discovery stage products.
The study further states that Medulloblastomas form because of errors in the machinery of the cell that controls the cell’s growth and death. Also, changes have been identified in genes and chromosomes (the cell’s DNA blueprints) that may play a role in the development of this tumor. Some of these gene changes can be targeted with new types of drugs, which are now being tested in clinical trials. Doctors who study and treat this disease expect that subgrouping will become vital to articulating treatment plans for these patients in the future.
Moreover, the study also reviews key players involved in the therapeutic development for vascular dementia and special features on late-stage and discontinued projects. The key players are adopting several competitive strategies such as collaborations, expansions and acquisitions to keep a strong foothold and gain an advantage in the therapeutic market.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1265408
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org